sarepta therapeutics - Search News

Order byBest matchMost fresh

Sarepta Therapeutics, gene

Sarepta Therapeutics Stock Plunges as Second Patient Dies Taking Its Drug

Key Takeaways Sarepta Therapeutics shares sank to their lowest level in nine years Monday after a second patient taking its Elevidys drug died.The patient was being treated for Duchenne muscular dystrophy,

· 10h · on MSN

Sarepta shares crash as second patient dies after receiving its gene therapy

· 10h · on MSN

Second patient death reported with gene therapy for muscular dystrophy

· 1d

Sarepta reports second case of liver failure death after its gene therapy treatment

U.S. consumer prices rose slightly in May as gasoline prices remained subdued, but inflation is likely to pick up in the months as tariffs boost the cost of imported goods.

· 19h

Sarepta crashes after second death linked to Roche-partnered Elevidys

· 1d

Sarepta Therapeutics: Rebuilding The Thesis After Hitting Rock Bottom

18h

Sarepta Therapeutics' Elevidys Liver Deaths Trigger Selloff, A Contrarian Opportunity

Sarepta's stock drops on ELEVIDYS safety concerns, yet potential remains for ambulatory patients. Click here to read an analysis of SRPT stock now.

10hon MSN

These Stocks Moved the Most Today: Sarepta, AMD, Tesla, U.S. Steel, Roku, Sage Therapeutics, and More

Stocks were rising Monday after The Wall Street Journal reported Tehran was looking to resume talks with the White House over its nuclear program in order to de-escalate a military conflict with Israel.

20h

Sarepta Therapeutics Stock Plummets Over 40% On Second Fatal Case Linked To Its Gene Therapy

Sarepta suspends Elevidys use in non-ambulatory Duchenne patients after two liver failure deaths, triggering FDA review and clinical trial pause.

Business Wire19h

Sarepta Provides Safety Update for ELEVIDYS and Initiates Steps to Strengthen Safety in Non-Ambulatory Individuals with Duchenne

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today provided a safety update regarding ELEVIDYS

18h

Sarepta Therapeutics, KULR Technology Group And Other Big Stocks Moving Lower In Monday's Pre-Market Session

Shares of Sarepta Therapeutics, Inc. SRPT fell sharply in today's pre-market trading after the company suspended ELEVIDYS shipments and paused ENVISION trial after second fatal liver failure in non-ambulatory Duchenne patients. Sarepta Therapeutics shares tumbled 31.4% to $24.86 in the pre-market trading session.

Explore more

Elevidys

Duchenne muscular dystrophy

STAT17h

Pharmalittle: We’re reading about a Sarepta setback with a DMD drug, FDA workload causes a delay, and more

In today's Pharmalittle roundup, we're reading about a Sarepta setback with its Duchenne drug, the FDA workload causing a delay, and more.